Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)
Hong Kong · Delayed Price · Currency is HKD 1.535
+0.060 (4.07%)
Sep 21, 2026, 11:28 AM HKT
HKG:2185 Revenue
Shanghai Bio-heart Biological Technology had revenue of 14.38M CNY in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to 38.45M, up 84.29% year-over-year. In the year 2025, Shanghai Bio-heart Biological Technology had annual revenue of 44.93M.
Revenue (ttm)
38.45M CNY
Revenue Growth
+84.29%
P/S Ratio
8.09
Revenue / Employee
610.27K CNY
Employees
63
Market Cap
359.04M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.93M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 549.77M |
| 3D Medicines | 412.66M |
| Cutia Therapeutics | 383.95M |
| JW (Cayman) Therapeutics Co. | 333.25M |
| Kintor Pharmaceutical | 90.90M |
| Wuhan YZY Biopharma | 72.52M |
| Brii Biosciences | 40.23M |
| Transcenta Holding | 32.70M |